GlaxoSmithKline | GSK - Interest Expense On Debt


GlaxoSmithKline reported GBP121M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alcon AG USD 52M 2M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 340M 144M Jun/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 79M 6M Mar/2026
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 104M 17M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Orion EUR 700K 700K Jun/2026
Pfizer USD 667M 4M Jun/2026
Philips EUR 83M 26M Mar/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Smith & Nephew USD 69M 1000K Dec/2025
UCB EUR 49M 29M Dec/2025